The New Mexico Medical Cannabis Program’s Medical Advisory Board voted to add Alzheimer’s Disease to the list  of medical conditions eligible for the Medical Cannabis Program. The Secretary of Health will have the final decision.

If approved by the Department of Health, New Mexico would join 13 other states where patients can access medical cannabis for Alzheimer’s disease and all other types of Neurodegenerative dementia.

Alzheimer’s disease, similar to many of the conditions presently included in New Mexico’s Compassionate Use Act, is a neurologic disease and has no known cure. Existing medications provide only temporary relief, without stopping the progression of the disease.

Peer reviewed studies suggest that medical cannabis may improve symptoms related to Alzheimer’s disease and support the pharmacological and physiological benefits seen in the use of cannabinoid compounds and whole plant medicine on general symptoms of neurodegeneration.

Professor Gary Wenk, of Ohio State University, whose research focuses on chronic brain inflammation and Alzheimer’s began studying cannabis compounds after other pharmaceuticals he studied “consistently failed to reduce inflammation in the brain.” Wenk’s animal study results show cannabis to be “the most potent brain anti-inflammatory available.”

Read Full Story On: drugpolicy


Leave a Reply

Your email address will not be published. Required fields are marked *

About Canna Magazine

This is the "wpengine" admin user that our staff uses to gain access to your admin area to provide support and troubleshooting. It can only be accessed by a button in our secure log that auto generates a password and dumps that password after the staff member has logged in. We have taken extreme measures to ensure that our own user is not going to be misused to harm any of our clients sites.

Category

Legislation News, Medical

Tags

, , , , , , , ,